ovarian cancer
Showing NaN - NaN of 107
Genetic Predisposition to Disease, Breast Cancer Female, Ovarian Cancer Trial in Philadelphia (Sequential EHR Communications)
Not yet recruiting
- Genetic Predisposition to Disease
- +6 more
- Sequential EHR Communications
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Feb 8, 2023
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified
Recruiting
- Endometrial Cancer
- +8 more
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
-
Orlando, Florida
- +21 more
Feb 2, 2023
Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)
Recruiting
- Advanced Malignancies
- +4 more
- Avelumab
- +7 more
-
Fayetteville, Arkansas
- +61 more
Jan 10, 2023
Ovarian Cancer, Cervical Cancer, Endometrial Cancer Trial in Worldwide (Enapotamab vedotin (HuMax-AXL-ADC))
Completed
- Ovarian Cancer
- +7 more
- Enapotamab vedotin (HuMax-AXL-ADC)
-
Phoenix, Arizona
- +40 more
Dec 12, 2022
Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma Trial in Philadelphia (huCART-meso cells)
Recruiting
- Lung Adenocarcinoma
- +5 more
- huCART-meso cells
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania
Dec 1, 2022
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Philadelphia (MOv19-BBz CAR T cells, Alpha Folate
Recruiting
- Ovarian Cancer
- +2 more
- MOv19-BBz CAR T cells
- Alpha Folate Receptor expression test
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania Health System
Sep 12, 2022
Ovarian Cancer, Breast Cancer Trial in Worldwide (Olaparib)
Enrolling by invitation
- Ovarian Cancer
- Breast Cancer
-
Boca Raton, Florida
- +98 more
Aug 22, 2022
Ovarian Cancer Trial in Washington, Baltimore, Philadelphia (Fostamatinib and Paclitaxel)
Active, not recruiting
- Ovarian Cancer
- Fostamatinib and Paclitaxel
-
Washington, District of Columbia
- +2 more
Aug 10, 2022
Urinary Bladder Cancer, Melanoma, Head Neck Cancer Trial in Canada, United States (Autologous genetically modified MAGE-A4?¹º³²T
Active, not recruiting
- Urinary Bladder Cancer
- +9 more
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
- Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
-
Miami, Florida
- +10 more
Aug 9, 2022
NSCLC, Ovarian Cancer, Fallopian Tube Cancer Trial in United States (CART-TnMUC1, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Non-Small Cell Lung Cancer
- +5 more
- CART-TnMUC1
- +2 more
-
Phoenix, Arizona
- +9 more
Jul 18, 2022
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer Trial in United States (NT-I7,
Recruiting
- Any Advanced Solid Tumors
- +6 more
-
Tampa, Florida
- +7 more
Jul 13, 2022
Ovarian Cancer Trial in Philadelphia (OTL38, intraoperative imaging camera system)
Withdrawn
- Ovarian Cancer
- OTL38
- intraoperative imaging camera system
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jun 23, 2022
Ovarian Cancer, Fatigue, Coping Behavior Trial in Boston, Philadelphia (Enhanced Usual Care (EOC), REVITALIZE ACT Intervention)
Active, not recruiting
- Ovarian Cancer
- +3 more
- Enhanced Usual Care (EOC)
- REVITALIZE ACT Intervention
-
Boston, Massachusetts
- +1 more
Jun 13, 2022
Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer Trial in United States (PY314, Combination Therapy: PY314 +
Recruiting
- Advanced Solid Tumor
- +8 more
- PY314
- Combination Therapy: PY314 + Pembrolizumab
-
Scottsdale, Arizona
- +12 more
Mar 28, 2022
Advanced Solid Tumors, Head Neck Cancer, Pancreatic Cancer Trial in United States (Cabiralizumab, Nivolumab)
Completed
- Advanced Solid Tumors
- +6 more
- Cabiralizumab
- Nivolumab
-
Scottsdale, Arizona
- +38 more
Jan 5, 2022
Breast Cancer, Prostate Cancer, Ovarian Cancer Trial in Worldwide (Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib, Part 1,
Completed
- Breast Cancer
- +2 more
- Part 1, Dose Level 1 and Dose Level 2a: Ipatasertib
- +3 more
-
San Marcos, California
- +16 more
Jan 25, 2022